Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Eprosartan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 known ✓ | P30556 | 2/20 | 0.92 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.92 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.92 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Eprosartan SCHEMBL5785067 | 1.00 | AGTR1 (0.92) | AGTR1ABCC3ABCC2 | |
| Eprosartan SCHEMBL3972893 | 1.00 | AGTR1 (0.92) | AGTR1ABCC3ABCC2 | |
| Eprosartan SCHEMBL41396 | 1.00 | AGTR1 (0.92) | AGTR1ABCC3ABCC2 | |
| Eprosartan SCHEMBL1504815 | 0.99 | AGTR1 (0.91) | AGTR1ABCC3ABCC2 | |
| Eprosartan SCHEMBL4382102 | 0.99 | AGTR1 (0.91) | AGTR1ABCC3ABCC2 | |
| Eprosartan SCHEMBL1504814 | 0.99 | AGTR1 (0.91) | AGTR1ABCC3ABCC2 | |
| Eprosartan SCHEMBL4382107 | 0.99 | AGTR1 (0.91) | AGTR1ABCC3ABCC2 | |
| Eprosartan SCHEMBL74813 | 0.97 | AGTR1 (0.92) | AGTR1ABCC3ABCC2 | |
| Eprosartan SCHEMBL156290 | 0.96 | AGTR1 (1.00) | AGTR1ABCC3ABCC2 | |
| Eprosartan SCHEMBL1815060 | 0.96 | AGTR1 (1.00) | AGTR1ABCC3ABCC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2797 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025131019-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF INHIBIN SUBUNIT BETA E (INHBE) | SHANGHAI ARGO BIOPHARMACEUTICAL CO., LTD. (CN) | 2025-06-26 | — | — | WO | claimed |
| US-20240252528-A1 | Methods Of Treating Metabolic Disorders And Cardiovascular Disease With Inhibin Subunit Beta E (INHBE) Inhibitors | REGENERON PHARMACEUTICALS, INC. | 2024-08-01 | — | — | US | claimed |
| CN-118325376-A | Antimicrobial coating and preparation method and application thereof | 泛领生物医学技术(苏州)有限公司 | 2024-07-12 | — | — | CN | claimed |
| EP-3737676-B1 | ACETAL COMPOUNDS AND THERAPEUTIC USES THEREOF | LIGAND PHARM INC (US) | 2024-03-06 | — | — | EP | claimed |
| US-11851443-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-12-26 | — | — | US | claimed |
| EP-4259279-A1 | METHODS OF TREATING METABOLIC DISORDERS AND CARDIOVASCULAR DISEASE WITH INHIBIN SUBUNIT BETA E (INHBE) INHIBITORS | REGENERON PHARMACEUTICALS, INC. (US) | 2023-10-18 | — | — | EP | claimed |
| US-11718591-B2 | Crystalline (2S,4R)-5-(5′-chloro-2′-fluoro-[1,1′-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2- methylpentanoic acid and uses thereof | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-08-08 | — | — | US | claimed |
| US-20230017661-A1 | COMPOSITIONS AND MODULAR NANO- AND MICROPARTICLES FOR THE DELIVERY OF VARIOUS AGENTS AND USE THEREOF | VERI NANO INC. (US) | 2023-01-19 | — | — | US | claimed |
| US-20220313726-A1 | Methods Of Treating Metabolic Disorders And Cardiovascular Disease With Inhibin Subunit Beta E (INHBE) Inhibitors | REGENERON PHARMACEUTICALS, INC. | 2022-10-06 | — | — | US | claimed |
| US-20220298173-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-09-22 | — | — | US | claimed |
| EP-0660713-B1 | USE OF ANGIOTENSIN II ANTAGONISTS IN THE TREATMENT OF LEFT VENTRICULAR HYPERTROPHY | SMITHKLINE BEECHAM PLC (GB) | 2001-10-24 | — | — | EP | claimed |
| EP-1098634-A2 | BIOENHANCED FORMULATIONS COMPRISING EPROSARTAN IN ORAL SOLID DOSAGE FORM | SmithKline Beecham Corporation (US) | 2001-05-16 | — | — | EP | claimed |
| EP-1061803-A1 | NOVEL COMPOSITIONS OF EPROSARTAN | SMITHKLINE BEECHAM CORPORATION (US) | 2000-12-27 | — | — | EP | claimed |
| WO-2000053282-A1 | CRYSTALLIZATION PROCESS FOR PRODUCING FINE CRYSTAL PRODUCTS | SMITHKLINE BEECHAM P.L.C. (GB) | 2000-09-14 | — | — | WO | claimed |
| WO-2000004862-A2 | BIOENHANCED FORMULATIONS COMPRISING EPROSARTAN IN ORAL SOLID DOSAGE FORM | SMITHKLINE BEECHAM CORPORATION (US) | 2000-02-03 | — | — | WO | claimed |
| WO-1999045779-A1 | NOVEL COMPOSITIONS OF EPROSARTAN | SMITHKLINE BEECHAM CORPORATION (US) | 1999-09-16 | — | — | WO | claimed |
| EP-0565634-B1 | ANGIOTENSIN II RECEPTOR BLOCKING COMPOSITIONS | SMITHKLINE BEECHAM CORP (US) | 1999-03-17 | — | — | EP | claimed |
| US-5656650-A | TREATING HYPERTENSION | SMITHKLINE BEECHAM CORP. | 1997-08-12 | — | — | US | claimed |
| WO-1993006828-A1 | MEDICAMENT FOR THE TREATMENT OF ANXIETY | SMITHKLINE BEECHAM CORPORATION (US) | 1993-04-15 | — | — | WO | claimed |
| US-5185351-A | Hypotensive agents; for treatment of congestive heart failure, renal failure and glaucoma | SMITHKLINE BEECHAM CORPORATION (US) | 1993-02-09 | — | — | US | claimed |